SecurityAZN / AstraZeneca Plc
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Shares2,421,400
Value $ 85,015,000
Related 046353AB4 / Astrazeneca 5.9% Senior Notes 9/15/17
046353AF5 / Astrazeneca Plc 1.95% 09/18/19
046353AG3 / Astrazeneca Plc 4.00% 09/18/42
046353AA6 / Astrazeneca Plc 5.40% Notes 06/01/2014
046353AD0 / Astrazeneca Plc 6.45% Senior Notes 9/15/37
98934KAB6 / Zeneca Wilmington Inc Guaranteed Debentures 7% 11/15/23

Citadel Advisors Llc reports 895.12% increase in ownership of AZN / AstraZeneca Plc

August 14, 2018 - Citadel Advisors Llc has filed a 13F-HR/A form disclosing ownership of 2,421,400 shares of AstraZeneca Plc (NYSE:AZN) with total holdings valued at $85,015,000 USD as of June 30, 2018. Citadel Advisors Llc had filed a previous 13F-HR/A on May 14, 2018 disclosing 243,327 shares of AstraZeneca Plc at a value of $8,509,000 USD. This represents a change in shares of 895.12 percent and a change in value of 899.12 percent during the quarter.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (AZN) in the form of stock options. The firm currently holds 251,700 call options valued at $8,838,000 USD and 93,300 put options valued at $3,276,000 USD .

Other investors with positions similar to Citadel Advisors Llc include York Capital Management Global Advisors, LLC, Royal Bank Of Canada, Dimensional Fund Advisors Lp, Ameriprise Financial Inc, UBS Group AG, and Morgan Stanley.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR/A-1 ASTRAZENECA Depository Receipt 046353108 35.04 2,421,400 895.12 85,015 899.12 76,319 187 2.20
2018-06-30 13F-HR ASTRAZENECA Depository Receipt 046353108 2,421,400 85,015
2018-03-31 13F-HR/A-1 ASTRAZENECA Depository Receipt 046353108 34.84 243,327 753.15 8,509 759.49 7,484 35 3.54
2018-03-31 13F-HR ASTRAZENECA Depository Receipt 046353108 243,327 8,509
2017-12-31 13F-HR ASTRAZENECA Depository Receipt 046353108 34.30 28,521 -95.44 990 -95.33 -20,461 271 1.28
2017-09-30 13F-HR ASTRAZENECA Depository Receipt 046353108 33.99 625,136 433.07 21,180 429.76 17,261 -79 -1.96
2017-06-30 13F-HR ASTRAZENECA Depository Receipt 046353108 32.62 117,270 -0.71 3,998 8.70 -27 347 9.45
2017-03-31 13F-HR ASTRAZENECA Depository Receipt 046353108 29.23 118,113 -75.13 3,678 -71.65 -10,428 1,132 8.72
2016-12-31 13F-HR ASTRAZENECA Depository Receipt 046353108 30.09 474,854 54.51 12,974 28.47 5,041 -2,166 -21.45
2016-09-30 13F-HR/A-1 ASTRAZENECA Depository Receipt 046353108 31.52 307,321 77.35 10,099 93.06 4,225 643 12.28
2016-09-30 13F-HR ASTRAZENECA PLC-SPONS ADR Depository Receipt 046353108 307,321 10,099
2016-06-30 13F-HR/A-1 ASTRAZENECA Depository Receipt 046353108 29.17 173,284 -81.56 5,231 -80.24 -22,366 1,129 4.26
2016-06-30 13F-HR ASTRAZENECA PLC-SPONS ADR Depository Receipt 046353108 173,284 5,231
2016-03-31 13F-HR/A-1 ASTRAZENECA Depository Receipt 046353108 939,918 0.00 26,468 26,468 0
2016-03-31 13F-HR ASTRAZENECA PLC-SPONS ADR Depository Receipt 046353108 939,918 26,468
2015-12-31 13F-HR/A-1 ASTRAZENECA PLC-SPONS ADR Depository Receipt 046353108 0 -100.00 0 -100.00 0 0
2015-09-30 13F-HR ASTRAZENECA PLC-SPONS ADR Depository Receipt 046353108 319,577 10,169
2015-06-30 13F-HR ASTRAZENECA GROUP PLC ADR 1:1 Depository Receipt 046353108 66.07 333,702 61.79 21,260 50.63 8,421 -1,275 -9.03
2015-03-31 13F-HR ASTRAZENECA GROUP PLC ADR 1:1 Depository Receipt 046353108 69.40 206,252 123.38 14,114 117.21 7,906 -290 -4.47
2014-12-31 13F-HR ASTRAZENECA GROUP PLC ADR 1:1 Depository Receipt 046353108 70.91 92,332 -37.91 6,498 -38.84 -3,997 -129 -1.21
2014-09-30 13F-HR ASTRAZENECA GROUP PLC ADR 1:1 Depository Receipt 046353108 72.88 148,703 52.49 10,624 46.62 3,730 -352 -4.86
2014-06-30 13F-HR ASTRAZENECA GROUP PLC ADR 1:1 Depository Receipt 046353108 69.59 97,516 912.10 7,246 1,059.36 6,115 506 80.90
2014-03-31 13F-HR ASTRAZENECA GROUP PLC ADR 1:1 Depository Receipt 046353108 9,635 625

Call Options

Effective
Date
Form Security Class CUSIP Opt Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR/A ASTRAZENECA Cmn 046353108 Call 35.04 251,700 -32.77 8,838 -32.50 -4,300 45 0.34
2018-06-30 13F-HR ASTRAZENECA Cmn 046353108 Call 251,700 8,838
2018-03-31 13F-HR/A ASTRAZENECA Cmn 046353108 Call 34.84 374,400 48.51 13,093 49.67 4,260 85 0.97
2018-03-31 13F-HR ASTRAZENECA Cmn 046353108 Call 374,400 13,093
2017-12-31 13F-HR ASTRAZENECA Cmn 046353108 Call 34.29 252,100 -49.77 8,748 -48.55 -8,566 310 1.82
2017-09-30 13F-HR ASTRAZENECA Cmn 046353108 Call 33.98 501,900 5.46 17,004 4.81 884 -103 -0.63
2017-06-30 13F-HR ASTRAZENECA Cmn 046353108 Call 32.61 475,900 97.14 16,223 115.82 7,648 1,058 14.07
2017-03-31 13F-HR ASTRAZENECA Cmn 046353108 Call 29.23 241,400 48.65 7,517 69.42 2,309 771 17.37
2016-12-31 13F-HR ASTRAZENECA Cmn 046353108 Call 30.09 162,400 -16.29 4,437 -30.40 -951 -987 -15.48
2016-09-30 13F-HR/A ASTRAZENECA Cmn 046353108 Call 31.53 194,000 -19.90 6,375 -12.81 -1,520 583 7.97
2016-09-30 13F-HR ASTRAZENECA PLC-SPONS ADR Cmn 046353108 Call 194,000 6,375
2016-06-30 13F-HR/A ASTRAZENECA Cmn 046353908 Call 30.19 242,200 0.00 7,312 0.00 0 0 0.00
2016-06-30 13F-HR ASTRAZENECA PLC-SPONS ADR Cmn 046353908 Call 242,200 7,312

Put Options

Effective
Date
Form Security Class CUSIP Opt Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR/A ASTRAZENECA Cmn 046353108 Put 35.04 93,300 -24.58 3,276 -24.27 -1,065 15 0.35
2018-06-30 13F-HR ASTRAZENECA Cmn 046353108 Put 93,300 3,276
2018-03-31 13F-HR/A ASTRAZENECA Cmn 046353108 Put 34.84 123,700 -27.24 4,326 -26.67 -1,613 40 0.68
2018-03-31 13F-HR ASTRAZENECA Cmn 046353108 Put 123,700 4,326
2017-12-31 13F-HR ASTRAZENECA Cmn 046353108 Put 34.29 170,000 7.73 5,899 10.34 418 135 2.52
2017-09-30 13F-HR ASTRAZENECA Cmn 046353108 Put 33.98 157,800 -42.01 5,346 -42.37 -3,884 -46 -0.49
2017-06-30 13F-HR ASTRAZENECA Cmn 046353108 Put 32.62 272,100 392.93 9,276 439.62 7,074 483 28.08
2017-03-31 13F-HR ASTRAZENECA Cmn 046353108 Put 29.23 55,200 -55.73 1,719 -49.55 -2,032 344 10.08
2016-12-31 13F-HR ASTRAZENECA Cmn 046353108 Put 30.09 124,700 -0.64 3,407 -17.39 -24 -693 -16.80
2016-09-30 13F-HR/A ASTRAZENECA Cmn 046353108 Put 31.53 125,500 27.67 4,124 38.95 858 298 10.06
2016-09-30 13F-HR ASTRAZENECA PLC-SPONS ADR Cmn 046353108 Put 125,500 4,124
2016-06-30 13F-HR/A ASTRAZENECA Cmn 046353958 Put 30.19 98,300 0.00 2,968 0.00 0 0 0.00
2016-06-30 13F-HR ASTRAZENECA PLC-SPONS ADR Cmn 046353958 Put 98,300 2,968

Related SEC Filings

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AstraZeneca SEC SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-02-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o (0-1)

Related News Stories

Agios Rides on Tibsovo Approval Amid Reliance on Celgene

22h zacks
On Oct 16, we issued an updated research report on Agios Pharmaceuticals, Inc. (AGIO - Free Report) . The company’s top line mainly consists of milestone payments and collaboration revenues on the net sales of Idhifa, which is owned by its partner Celgene Corporation (CELG - Free Report) . Its wholly owned product Tibsovo was approved by the FDA in July 2018 and holds immense commercial potential in the acute myeloid leukemia (AML) market. (9-0)

Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

23h zacks
On Oct 16, we issued an updated research report on Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) . This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of treatments primarily addressing gastrointestinal (“GI”) diseases. The company’s sole marketed drug, Linzess, is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (“CIC”). (6-1)

QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite

23h zacks
QIAGEN N.V. (QGEN - Free Report) recently announced the European launch of its next-generation multiplex gastrointestinal panel — QIAstat-Dx panel. This completely integrated molecular analysis of gastrointestinal (GI) syndromes analyzes and detects the 24 most common viral, bacterial and parasitic pathogens which can cause GI infections. (4-0)

The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke

23h zacks
Chicago, IL –October 19, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca (AZN - Free Report) , salesforce.com (CRM - Free Report) , Mastercard (MA - Free Report) , Lam Research (LRCX - Free Report) and Koninklijke Philips (PHG - Free Report) . (12-0)

Top Analyst Reports for AstraZeneca, Salesforce & Mastercard

2018-10-19 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca (AZN), salesforce.com (CRM) and Mastercard (MA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (5-0)



CUSIP: 046353108